Core Viewpoint - Nexalin Technology, Inc. has launched a new AI-designed virtual clinic platform, NeuroCare®, in partnership with UC San Diego, aimed at enhancing access to neurotherapy for brain health disorders while reducing costs and stigma associated with treatment [1][5] Group 1: Product and Technology - The NeuroCare platform allows patients with conditions such as Alzheimer's, mood disorders, and military-related issues to use Nexalin's HALO headset for neurostimulation treatment at home [2][4] - The Gen-3 HALO™ headset integrates with the NeuroCare platform, providing a comprehensive ecosystem for remote physician oversight and advanced therapy delivery [4] Group 2: Business Model and Market Strategy - The NeuroCare platform operates on a subscription-based model, promoting sustainable revenue and long-term patient outcomes [2][3] - Nexalin aims to transition from device sales to long-term recurring revenue through data-driven clinical outcomes and patient retention strategies [4][5] Group 3: Clinical Research and Development - The collaboration with UC San Diego builds on ongoing clinical research, with patient enrollment already underway for trials evaluating Nexalin's non-invasive treatment methods [1][4] - The launch of the Gen-3 HALO headset is part of a broader strategy to address the global mental health epidemic through innovative neurostimulation technology [6]

Core Viewpoint - RenovoRx has appointed Mark Voll as Chief Financial Officer to enhance its leadership team and support the commercialization of its RenovoCath drug-delivery device, marking a significant transition from a clinical stage to a commercial company [1][4]. Group 1: Appointment and Leadership - Mark Voll brings over 30 years of financial leadership experience, having successfully guided high-growth public companies through commercial development [2]. - Voll's role will focus on stockholder communications, budgeting, strategic planning, and finance, which are crucial as RenovoRx commercializes RenovoCath and advances its Phase III TIGeR-PaC clinical trial [3][4]. - CEO Shaun Bagai expressed confidence in Voll's ability to drive sustained commercial execution during this pivotal time for the company [4]. Group 2: Company Overview and Product Information - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed for targeted therapeutic delivery [7]. - RenovoCath is intended for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including arteriography and chemotherapeutic drug infusion [6]. - The company has begun commercializing the TAMP therapy platform and RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8]. Group 3: Clinical Trials and Future Prospects - RenovoRx is evaluating a novel drug-device combination candidate, IAG, in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9][10]. - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10].

Core Insights - Microbot Medical Inc. is participating in the Society of Interventional Oncology (SIO) annual meeting to share insights and experiences regarding its LIBERTY Endovascular Robotic System, which is currently in a limited market release phase [1][2] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [3][4] - The company aims to accelerate commercial awareness and adoption of the LIBERTY System through direct engagement with interventional oncologists at the conference [1][2] Company Overview - Microbot Medical Inc. focuses on transforming endovascular procedures with advanced robotic technology, highlighted by the LIBERTY Endovascular Robotic System [4] - The company has a strong intellectual property portfolio and is committed to innovation in the medical device sector [4] Market Context - The interventional oncology market is described as a large and expanding multi-billion dollar sector, with increasing procedure volumes driving demand for advanced technologies like LIBERTY [2] - The full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference [3]

Core Insights - Boston Scientific Corporation reported strong fourth-quarter earnings for 2025, with revenues of $5.29 billion, slightly above the consensus estimate of $5.28 billion and exceeding management guidance of $5.22 billion to $5.31 billion [1] - The company achieved adjusted earnings of 80 cents per share, surpassing the consensus of 78 cents and management guidance of 77 to 79 cents [1] Revenue Forecast - For 2026, Boston Scientific forecasts net sales growth of approximately 10.5% to 11.5% on a reported basis and 10% to 11% organically, with expected sales between $22.18 billion and $22.38 billion, compared to the consensus of $22.37 billion [2] - The company estimates adjusted earnings per share for 2026 to be between $3.43 and $3.49, against the consensus of $3.47 [2] Market Reaction - Following the earnings announcement, Boston Scientific shares increased by 0.6%, reaching $75.92 in pre-market trading [2] - Analysts have adjusted their price targets for Boston Scientific in response to the earnings results [3]

Earnings Conference Call Fiscal Q1 2026 February 5, 2026 1 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans and achievemen ...

Core Viewpoint - Inspira Technologies has announced a registered direct offering of 6,785,715 ordinary shares at a price of $0.70 per share, expected to raise approximately $4.75 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on or about February 6, 2026, pending customary closing conditions [2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [2]. Group 2: Securities and Registration - The ordinary shares are being offered under a prospectus supplement to be filed with the SEC, linked to the Company's effective shelf registration statement [3]. - The warrants issued in a concurrent private placement will have an exercise price of $0.70 per share and will be exercisable six months after issuance, expiring in 5.5 years [1][3]. Group 3: Existing Warrants Amendment - Existing warrants issued to the investor in December 2023, originally priced at $1.28, will be amended to a reduced exercise price of $0.70 per share, expiring five years from the closing date [5]. Group 4: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [6]. - The company is developing the INSPIRA ART500 system for oxygenation while patients remain awake and is advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [6]. - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech sectors [6].

FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference. The event, hosted by Scripps Health, will take place from February 11–13, 2026, at the Hyatt Regency La Jolla at Aventine in San Diego. The Scripp ...

Core Insights - Profound Medical Corp. has achieved a significant milestone with the completion of its 500th Sonalleve Procedure at PRO FAMILIA Specialist Hospital in Poland, reflecting the growing adoption of non-surgical treatment options for uterine conditions [1][2] - The Sonalleve technology offers a non-invasive alternative for treating uterine fibroids and adenomyosis, providing targeted relief without incisions, blood loss, or the need for overnight hospital stays [1][2] - The company is also focused on the commercialization of TULSA-PRO, which is designed for prostate disease treatment, emphasizing its unique ability to minimize side effects associated with traditional surgical methods [3][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company that specializes in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] - The company is actively commercializing two main products: TULSA-PRO for prostate conditions and Sonalleve for gynecologic disorders, both of which utilize advanced imaging and therapeutic technologies [5][7] Product Details - Sonalleve has been operational in Europe, China, and Southeast Asia, with over 4,000 women treated for uterine conditions, demonstrating effective pain and symptom relief while preserving fertility [2][3] - TULSA-PRO employs real-time MRI guidance and is designed to treat a wide range of prostate diseases, ensuring preservation of urinary continence and sexual function [5][6] - Both Sonalleve and TULSA-PRO have received various regulatory approvals, including CE marking and FDA clearance, indicating their compliance with safety and efficacy standards [6][7]

Third Quarter Fiscal 2026 Results February 5, 2026 © 2026 Haemonetics Corporation Q3 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on February 5, 2026, and can be accessed via live webcast: Link or teleconference: Link. The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com. Conference call speakers: Chris Simon President & CEO James D'Arecca EVP, Chief Financial Officer Olga Gu ...

The U.S. medical device market is filled with companies that have innovative technology, but my bullish outlook on Establishment Labs ( ESTA ) is not based solely upon the successful launch of the Motiva breast implantsI am an investor specializing in the consumer products sector with a focus on identifying companies that offer a unique combination of strong brand recognition, solid financials, and growth potential. I have a keen eye for consumer trends and an in-depth understanding of the industry, which h ...